港股创新药ETF（159567）跌1.90%，成交额34.73亿元

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown significant growth in both share volume and fund size since its inception, despite a recent decline in its closing price [1][2]. Group 1: Fund Performance - As of September 10, 2024, the Hong Kong Innovative Drug ETF (159567) had a total share volume of 6.892 billion shares and a total fund size of 6.859 billion yuan [1]. - The fund's share volume increased by 1643.13% and its size increased by 1715.37% compared to December 31, 2023, when the share volume was 395 million shares and the size was 378 million yuan [1]. Group 2: Trading Activity - The ETF recorded a trading volume of 34.73 billion yuan on September 11, 2024, with a closing price decline of 1.90% [1]. - Over the past 20 trading days, the cumulative trading amount reached 35.879 billion yuan, averaging 1.794 billion yuan per day; since the beginning of the year, the cumulative trading amount was 194.73 billion yuan, averaging 1.145 billion yuan per day [1]. Group 3: Fund Management - The current fund manager, Ma Jun, has managed the Hong Kong Innovative Drug ETF (159567) since its inception, achieving a return of 99.04% during the management period [2]. - The ETF's top holdings include companies such as Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant percentages of the portfolio allocated to these stocks [2].